By the time you finish reading this article, the world will be experiencing a major pandemic with COVID infections that will make it impossible to get the very medicines that have saved lives in the past. 

But a lot of the drugs that will save lives for decades to come are not on the COVID prescription list, and so they are unlikely to make it into the hands of consumers who need them. 

The drugs that are on the list are the drugs listed on the Generic Generic Drug Interim List (GDLI), a list of drugs that can be bought and used in the United States, Canada, Mexico, and other countries. 

If you’re not on this list, you can’t buy these drugs.

While it’s unclear how many of the generics on the GDLI are generic, it’s likely that more than half of the GDRI drugs listed here are not in the US market, meaning that they will be inaccessible to people who need the drugs.

This is particularly important, since the vast majority of these drugs have been on the US prescription list for decades, and many of them have been used in large numbers to fight the pandemic. 

We spoke to several doctors who work on the side of health care workers who have had to deal with COFFIN, a COVID vaccine, to get their patients into the US. 

Dr. Daniel Eberhardt, a professor at the University of Texas Health Science Center at San Antonio, told us that while he is a proponent of the generic option, “the reason I’m using generic is not because it’s cheaper, it is because I’m not a patient.

It’s a different way of thinking.

I’m a clinician, I have a lot more patients than I can keep up with. 

I can’t get patients to take generic, so I have to pay a lot to get them to take my own generic, which I think is a much better option.” 

Dr, William Mazzocco, a clinical professor of emergency medicine at the Johns Hopkins University, told The Verge that “the problem with the GDAI is that it’s so small that you can only afford to buy it once a year. 

It’s so narrow that you have to spend a lot on it, so you can save up to 10% off.”

The lack of generics in the GDI list has resulted in a shortage of drugs for people who really need them, according to Dr. David Zillman, a medical director for the Healthcare Leadership Institute, a healthcare advocacy group. 

“A lot of people are having to do their own research on who needs what, what’s available, and where they’re getting their supplies,” Zillmen told us. 

As of now, the generic options are limited to a limited list of about 500 drugs, and Dr. Zillmans estimate that “a lot of them aren’t even on the market yet.” 

Zillman told us he hopes to start the generic market for COFFI in the next couple of weeks, but he said he doesn’t have a specific timeline yet, because “we’re still waiting for [the generic] drugs to be approved. 

In addition to these problems, the generically-supplied drugs aren’t very effective in the hands a patient might be using them for. 

There are no indications for their use outside of the United Kingdom, and there are very few studies to prove that they actually work,” Zellman said. 

He added that the US generic option has proven so successful in the UK that he is optimistic that it will be able to reach the US, and added, “I’d be willing to bet that by the end of the year, there will be more generic drugs available to the US that can treat COFF.” 

We reached out to Drs.

Zellmans and Eberhart to get more information about the generals that are available, as well as how they’re being used. 

Zellmans told us, “The only one that we have is a generic called COVID7.

It has no indication of efficacy in the clinical setting.

It will only work in the clinic and it will not work in a hospital setting.”

Dr. Eberhard added that he hopes the Gdli will be ready for the US soon, and he hopes that “this is just the first step to a generic drug market in the U.S.”

“We want to get COFFi out of the UK, and we’re working on that, but we’re also working on other things like expanding access to COVID drugs in Europe,” Eberhd said.

The Generic Drug Inventory (GDI) is a list that is compiled every month by the US Food and Drug Administration, which tracks all new drugs and makes sure that they meet the standards for generic status. 

GDI is compiled by the